User profiles for James R Goodhand
 | James GoodhandRoyal Devon and Exeter NHS Foundation Trust Verified email at nhs.net Cited by 4353 |
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Background Anti-TNF drugs are effective treatments for the management of Crohn's disease
but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors …
but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors …
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Objective Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for
a lower level of immunity across more of the population. We investigated whether patients …
a lower level of immunity across more of the population. We investigated whether patients …
[HTML][HTML] COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case …
…, DM Altmann, RJ Boyton, JR Goodhand… - The lancet …, 2022 - thelancet.com
Background The effects that therapies for inflammatory bowel disease (IBD) have on immune
responses to SARS-CoV-2 vaccination are not yet fully known. Therefore, we sought to …
responses to SARS-CoV-2 vaccination are not yet fully known. Therefore, we sought to …
[HTML][HTML] HLA-DQA1* 05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease
Background & Aims Anti–tumor necrosis factor (anti-TNF) therapies are the most widely
used biologic drugs for treating immune-mediated diseases, but repeated administration can …
used biologic drugs for treating immune-mediated diseases, but repeated administration can …
[HTML][HTML] Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with …
…, DM Altmann, RJ Boyton, JR Goodhand… - Nature …, 2022 - nature.com
Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection
and impair protective immunity following pneumococcal and influenza vaccination. Here we …
and impair protective immunity following pneumococcal and influenza vaccination. Here we …
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
NA Kennedy, JR Goodhand, C Bewshea, R Nice… - Gut, 2021 - gut.bmj.com
Objective Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following
pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious …
pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious …
Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease
JR Goodhand, N Kamperidis, A Rao… - Inflammatory bowel …, 2012 - academic.oup.com
Background Children and adolescents with inflammatory bowel disease (IBD) are more
likely to have Crohn's disease (CD) than ulcerative colitis (UC) and their disease tends to be …
likely to have Crohn's disease (CD) than ulcerative colitis (UC) and their disease tends to be …
[HTML][HTML] COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP) …
Background COVID-19 vaccine-induced antibody responses are reduced in patients with
inflammatory bowel disease (IBD) taking anti-TNF or tofacitinib after two vaccine doses. We …
inflammatory bowel disease (IBD) taking anti-TNF or tofacitinib after two vaccine doses. We …
Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease
…, R Xavier, R Ward, MN Weedon, JR Goodhand… - Jama, 2019 - jamanetwork.com
Importance Use of thiopurines may be limited by myelosuppression.TPMTpharmacogenetic
testing identifies only 25% of at-risk patients of European ancestry. Among patients of East …
testing identifies only 25% of at-risk patients of European ancestry. Among patients of East …
Systematic review: Clostridium difficile and inflammatory bowel disease
JR Goodhand, W Alazawi… - Alimentary pharmacology …, 2011 - Wiley Online Library
Background There is increasing concern about the apparently rising incidence and
worsening outcome of Clostridium difficile infection (CDI) associated with inflammatory bowel …
worsening outcome of Clostridium difficile infection (CDI) associated with inflammatory bowel …
